FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, in particular, a method for validating purification from viruses in a continuous mode is disclosed, including stages of: providing a sample to be validated, adding an additive to this sample for analysis in an acceptable way, performing purification from viruses, sampling from a sample with an added additive for analysis and analyzing a sample from a sample with an added additive for analysis.
EFFECT: technical result is obtaining a method for validation of virus purification in a continuous mode.
5 cl, 6 dwg, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR LIQUID INCUBATION AND VIRAL INACTIVATION | 2018 |
|
RU2779191C2 |
| VIRUS INACTIVATION METHODS FOR CONTINUOUS ANTIBODY PRODUCTION | 2019 |
|
RU2807176C2 |
| METHODS OF VIRUS INACTIVATION USING ENVIRONMENTAL-FRIENDLY DETERGENTS | 2014 |
|
RU2707951C1 |
| IMPROVED PROTEIN PURIFICATION BY MEANS OF MODIFIED ELUATING OF PROTEIN A | 2010 |
|
RU2571929C2 |
| IMPROVED METHODS OF PURIFYING VECTORS BASED ON RECOMBINANT AAV | 2010 |
|
RU2588387C2 |
| METHODS OF PRODUCING COMPOSITIONS WITH IMPROVED SAFETY PROFILE CONTAINING PANCREATIN, AND COMPOSITIONS SUITABLE FOR PHARMACEUTICAL USE | 2015 |
|
RU2712142C2 |
| ISOLATION AND PURIFICATION OF ANTI-IL-13 ANTIBODIES USING PROTEIN A AFFINITY CHROMATOGRAPHY | 2010 |
|
RU2603055C2 |
| METHOD OF OBTAINING INACTIVATED VACCINE AGAINST COVID-19 AND VACCINE OBTAINED BY METHOD | 2023 |
|
RU2810740C1 |
| VIRUS INACTIVATION IN ANTIBODY PURIFICATION | 2009 |
|
RU2551237C2 |
| WHOLE VIRION INACTIVATED VACCINE AGAINST SARS-Cov-2 INFECTION AND ITS USE | 2023 |
|
RU2809375C1 |
